Home  »  Finance   »  Aclaris Therapeutics Inc. (ACRS) Sits And Waits Fo...

Aclaris Therapeutics Inc. (ACRS) Sits And Waits For Direction At $7.55 Price

Aclaris Therapeutics Inc. (NASDAQ:ACRS) concluded the trading at $7.55 on Friday, September 15 with a fall of -5.62% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $8.00 and 5Y monthly beta was reading 0.66 with its price kept floating in the range of $7.45 and $8.18 on the day. Considering stock’s 52-week price range provides that ACRS hit a high price of $18.96 and saw its price falling to a low level of $5.77 during that period. Over a period of past 1-month, stock came subtracting -2.20% in its value.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


With its current market valuation of $519.36 million, Aclaris Therapeutics Inc. is set to declare its quarterly results on Nov 06, 2023 – Nov 10, 2023. Analysts are in estimates of -$0.48 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.79 for 2023 with estimates of that growing to -$1.86 in next year. These estimates are suggesting current year growth of -34.60% for EPS and -3.90% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $1.57 million. They suggested that in the process company could generate revenue of as low as $870k which could climb up to $2.22 million to hit a high. The average estimate is representing a decrease of -1.90% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $7.57 million in 2023, which will be -74.60% less from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with 1 upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review ACRS stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.

Digging deeper we become aware of the PEG ratio of the ACRS stock which is currently positioned at 0. It further provides that stock’s current price level is 1.10% away from its 20-day simple moving average and is -14.42% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 44.05 while volatility remained at 5.45% over the past week which changes to 6.64% when measuring it over the past month. Beta is valued at 0.65, while measure of average true range or ATR is currently at 0.48.

In comparing Aclaris Therapeutics Inc. (ACRS)’s stock with other industry players reveals that stock’s current price change of -5.62% and that of -49.70% over the past 12 months. Industry’s another major player Omeros Corporation (OMER) has fall -2.51% down in previous session, but over the past year has faced a fall of -42.30% over the same period. Aclaris Therapeutics Inc. has a P/E ratio of 0. On the other hand, the S&P 500 Index was down -1.22% in the last trading session while the Dow Jones Industrial closed the session lower at -0.83%.

Having a second look at Aclaris Therapeutics Inc. (NASDAQ:ACRS) provides that stock’s average daily trading volume for 3 months was 713.18K, while it jumped to 1.05 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 70.63 million.

The percentage of outstanding shares held by the insiders is 0.20% while it is 96.50% for the institutional holders. The figures also indicate that as of Aug 30, 2023, number of stock’s short shares was 5.7 million which implies a short ratio of 8.15. This shows up a 8.05% of Short Interest in company’s outstanding shares on the day. In August the standing of shares short improved as it was 5.21 million in the previous month. Subtraction of -52.06% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.